FDA gives Durham's BioCryst green light to resume enrollment in multiple trials

A Durham drugmaker can resume enrolling patients in multiple clinical trials after getting the OK from regulators.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 7, 2022 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news